Wigan Eye Drops

Brimonidine Tartrate + Timolol Maleate Eye prep

(200 mg + 500 mg)/100 ml

Healthcare Pharmaceuticals Ltd.

Pack size
Dispensing mode
Source
Agent
Retail Price	120.00 AED

Indications

Wigan Eye Drops is used for: Open-angle glaucoma, Ocular hypertension

Adult Dose

Adult: Ophth: One drop in the affected eye(s), twice daily approximately 12 hours apart.

Child Dose

Not for use in children below the age of 2 years. Use with caution in children > 2 years of age.

Renal Dose

Administration

Contra Indications

Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock. Neonates and infants (under the age of 2 years). Hypersensitivity to any component of this product.

Precautions

Potential for Severe Respiratory or Cardiac Reactions Cardiac Failure Obstructive Pulmonary Disease Potentiation of Vascular Insufficiency Increased Reactivity to Allergens Potentiation of Muscle Weakness Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Masking of Thyrotoxicosis Ocular Hypersensitivity

Pregnancy-Lactation

Pregnancy There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent; because animal reproduction studies are not always predictive of human response, this drug combination should be used during pregnancy only if potential benefit to mother justifies potential risk to fetus Teratogenicity studies have been performed in animals; brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits; the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achieved AUC exposure values 580 and37-fold higher, respectively than similar values estimated in humans treated with this drug combination, 1 drop in both eyes twice daily Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day [4,200 times maximum recommended human ocular dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)] demonstrated no evidence of fetal malformations; although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring; doses of 1,000 mg/kg/day (83,000 times the MRHOD) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses 8,300 times the MRHOD without apparent maternotoxicity Lactation Timolol has been detected in human milk following oral and ophthalmic drug administration; it is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk; because of potential for serious adverse reactions from this drug combination in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Interactions

Antihypertensives/cardiac glycosides may lower blood pressure. Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia. Use with CNS depressants may result in an additive or potentiating effect. Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. CYP2D6 inhibitors may potentiate systemic beta-blockade. Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. Monoamine oxidase inhibitors may result in increased hypotension. Contraindicated (4) isocarboxazid linezolid mavorixafor phenelzine

Adverse Effects

Side effects of Brimonidine Tartrate + Timolol Maleate Eye prep : 5-15% Allergic conjunctivitis,Conjunctival folliculosis,Conjunctival hyperemia,Eye pruritus,Ocular burning,Stinging 1-5% Asthenia,Blepharitis,Corneal erosion,Depression,Epiphora,Eye discharge,Eye dryness,Eye irritation,Eye pain,Eyelid edema,Eyelid erythema,Eyelid pruritus,Foreign body sensation,Headache,Hypertension,Oral dryness,Somnolence,Superficial punctate keratitis,Visual disturbance

Mechanism of Action

Brimonidine is an alpha 2-adrenoceptor agonist which works to reduce aqueous humor production and increase uveoscleral flow. Timolol is a non-selective beta-adrenergic receptor blocker. It does not have significant intrinsic sympathomimetic activity, direct myocardial depressant activity or local anaesth activity. Exact mechanism of ocular hypotensive effect is unclear, but it is thought to be related to reduction of aqueous humour formation. beta-blockade also causes lowering of BP.

Note

Wigan (200 mg + 500 mg)/100 ml Eye Drops manufactured by Healthcare Pharmaceuticals Ltd.. Its generic name is Brimonidine Tartrate + Timolol Maleate Eye prep. Wigan is availble in Bangladesh. Farmaco BD drug index information on Wigan Eye Drops is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Brimonidine Tartrate + Timolol Maleate Eye prep :

Eye Drops

Brimodin Plus ^{200 mg + 500 mg/100 ml}

Incepta Pharmaceuticals Ltd.

Eye Drops

Combat ^0.2%+0.5%

General Pharmaceuticals Ltd.

Eye Drops

Combipres ^{0.2% + 0.5%}

Aristopharma Limited

Eye Drops

Timo-plus ^{200 mg + 500 mg/100 ml}

Reman Drug Laboratories Ltd.

Eye Drops

Brimopres ^{0.2% + 0.5%}

Popular Pharmaceuticals Ltd.